LANGHORNE, Pa. / Jan 31, 2024 / Business Wire / Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences:
Guggenheim 6th Annual Biotechnology Conference
February 7, 2024 at 8:30am PT/ 11:30am ET
Fireside Chat
St. Regis Hotel, New York City, NY
Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 13, 2024 at 7:40am PT / 10:40am ET
Corporate Presentation
Virtual Conference
A webcast of each presentation will be available through the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for at least 30 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
| Last Trade: | US$3.13 |
| Daily Change: | 0.19 6.46 |
| Daily Volume: | 6,070,240 |
| Market Cap: | US$515.200M |
September 27, 2024 September 23, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
